The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma

Randy Yeh, Laurent Dercle, Ishan Garg, Zhen Jane Wang, David M Hough, Ajit Goenka

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains a difficult disease to treat and continues to portend a poor prognosis, as most patients are unresectable at diagnosis. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) combined with CT (PET/CT) has been a cornerstone in oncological imaging of different cancers; however, the role of PET/CT in PDAC is continually evolving and currently not well established. Studies have shown the potential of PET/CT in guiding the management of patients with PDAC, with possible added benefit over anatomic imaging with CT or MRI in certain scenarios. PET/CT may be useful in diagnosis, initial staging, treatment response assessment, differentiation of recurrent tumor from post-treatment fibrosis, and radiotherapy planning. Additionally, PET/CT may be a cost-effective modality due to upstaging of patients originally deemed as surgical candidates. Recently, the advent of simultaneous PET/MRI represents an exciting advancement in hybrid functional imaging with potential applications in the imaging of PDAC. The advantages of PET/MRI include simultaneous acquisition to improve registration of fusion images, lower radiation dose, superior soft tissue contrast, and availability of multiparametric imaging. Studies are underway to evaluate the utility of PET/MRI in PDAC, including in initial staging and treatment response assessment and to determine the subgroup of patients that will benefit from PET/MRI. Further studies are warranted in both PET/CR and PET/MRI to better understand the role of these modalities in PDAC.

Original languageEnglish (US)
Pages (from-to)1-20
Number of pages20
JournalAbdominal Radiology
DOIs
StateAccepted/In press - Nov 16 2017

Fingerprint

Fluorodeoxyglucose F18
Positron-Emission Tomography
Adenocarcinoma
Multimodal Imaging
Neoplasms
Fibrosis
Radiotherapy
Therapeutics
Radiation

Keywords

  • 18F-fluorodeoxyglucose
  • Pancreatic cancer
  • PET/CT
  • PET/MRI
  • Positron emission tomography (PET)

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging
  • Gastroenterology
  • Urology

Cite this

The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma. / Yeh, Randy; Dercle, Laurent; Garg, Ishan; Wang, Zhen Jane; Hough, David M; Goenka, Ajit.

In: Abdominal Radiology, 16.11.2017, p. 1-20.

Research output: Contribution to journalArticle

Yeh, Randy ; Dercle, Laurent ; Garg, Ishan ; Wang, Zhen Jane ; Hough, David M ; Goenka, Ajit. / The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma. In: Abdominal Radiology. 2017 ; pp. 1-20.
@article{1fbf29cf434c4cdf8a50e9a9405bba13,
title = "The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) remains a difficult disease to treat and continues to portend a poor prognosis, as most patients are unresectable at diagnosis. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) combined with CT (PET/CT) has been a cornerstone in oncological imaging of different cancers; however, the role of PET/CT in PDAC is continually evolving and currently not well established. Studies have shown the potential of PET/CT in guiding the management of patients with PDAC, with possible added benefit over anatomic imaging with CT or MRI in certain scenarios. PET/CT may be useful in diagnosis, initial staging, treatment response assessment, differentiation of recurrent tumor from post-treatment fibrosis, and radiotherapy planning. Additionally, PET/CT may be a cost-effective modality due to upstaging of patients originally deemed as surgical candidates. Recently, the advent of simultaneous PET/MRI represents an exciting advancement in hybrid functional imaging with potential applications in the imaging of PDAC. The advantages of PET/MRI include simultaneous acquisition to improve registration of fusion images, lower radiation dose, superior soft tissue contrast, and availability of multiparametric imaging. Studies are underway to evaluate the utility of PET/MRI in PDAC, including in initial staging and treatment response assessment and to determine the subgroup of patients that will benefit from PET/MRI. Further studies are warranted in both PET/CR and PET/MRI to better understand the role of these modalities in PDAC.",
keywords = "18F-fluorodeoxyglucose, Pancreatic cancer, PET/CT, PET/MRI, Positron emission tomography (PET)",
author = "Randy Yeh and Laurent Dercle and Ishan Garg and Wang, {Zhen Jane} and Hough, {David M} and Ajit Goenka",
year = "2017",
month = "11",
day = "16",
doi = "10.1007/s00261-017-1374-2",
language = "English (US)",
pages = "1--20",
journal = "Abdominal Radiology",
issn = "2366-004X",
publisher = "Springer New York",

}

TY - JOUR

T1 - The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma

AU - Yeh, Randy

AU - Dercle, Laurent

AU - Garg, Ishan

AU - Wang, Zhen Jane

AU - Hough, David M

AU - Goenka, Ajit

PY - 2017/11/16

Y1 - 2017/11/16

N2 - Pancreatic ductal adenocarcinoma (PDAC) remains a difficult disease to treat and continues to portend a poor prognosis, as most patients are unresectable at diagnosis. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) combined with CT (PET/CT) has been a cornerstone in oncological imaging of different cancers; however, the role of PET/CT in PDAC is continually evolving and currently not well established. Studies have shown the potential of PET/CT in guiding the management of patients with PDAC, with possible added benefit over anatomic imaging with CT or MRI in certain scenarios. PET/CT may be useful in diagnosis, initial staging, treatment response assessment, differentiation of recurrent tumor from post-treatment fibrosis, and radiotherapy planning. Additionally, PET/CT may be a cost-effective modality due to upstaging of patients originally deemed as surgical candidates. Recently, the advent of simultaneous PET/MRI represents an exciting advancement in hybrid functional imaging with potential applications in the imaging of PDAC. The advantages of PET/MRI include simultaneous acquisition to improve registration of fusion images, lower radiation dose, superior soft tissue contrast, and availability of multiparametric imaging. Studies are underway to evaluate the utility of PET/MRI in PDAC, including in initial staging and treatment response assessment and to determine the subgroup of patients that will benefit from PET/MRI. Further studies are warranted in both PET/CR and PET/MRI to better understand the role of these modalities in PDAC.

AB - Pancreatic ductal adenocarcinoma (PDAC) remains a difficult disease to treat and continues to portend a poor prognosis, as most patients are unresectable at diagnosis. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) combined with CT (PET/CT) has been a cornerstone in oncological imaging of different cancers; however, the role of PET/CT in PDAC is continually evolving and currently not well established. Studies have shown the potential of PET/CT in guiding the management of patients with PDAC, with possible added benefit over anatomic imaging with CT or MRI in certain scenarios. PET/CT may be useful in diagnosis, initial staging, treatment response assessment, differentiation of recurrent tumor from post-treatment fibrosis, and radiotherapy planning. Additionally, PET/CT may be a cost-effective modality due to upstaging of patients originally deemed as surgical candidates. Recently, the advent of simultaneous PET/MRI represents an exciting advancement in hybrid functional imaging with potential applications in the imaging of PDAC. The advantages of PET/MRI include simultaneous acquisition to improve registration of fusion images, lower radiation dose, superior soft tissue contrast, and availability of multiparametric imaging. Studies are underway to evaluate the utility of PET/MRI in PDAC, including in initial staging and treatment response assessment and to determine the subgroup of patients that will benefit from PET/MRI. Further studies are warranted in both PET/CR and PET/MRI to better understand the role of these modalities in PDAC.

KW - 18F-fluorodeoxyglucose

KW - Pancreatic cancer

KW - PET/CT

KW - PET/MRI

KW - Positron emission tomography (PET)

UR - http://www.scopus.com/inward/record.url?scp=85034256371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034256371&partnerID=8YFLogxK

U2 - 10.1007/s00261-017-1374-2

DO - 10.1007/s00261-017-1374-2

M3 - Article

C2 - 29143875

AN - SCOPUS:85034256371

SP - 1

EP - 20

JO - Abdominal Radiology

JF - Abdominal Radiology

SN - 2366-004X

ER -